The most common failure in health technology is not a product that does not work. It is a product that works, in a pilot, for eighteen months, and never becomes a line item in an operating budget.
I have watched this from both sides of the table, and the pattern is consistent enough to be predictable. It is worth naming precisely, because founders usually diagnose it as a sales problem when it is almost always a structural one.
The five structural reasons
The pilot had no budget owner. Innovation funds, grant money, a departmental discretionary pot and a CMIO's enthusiasm can all fund a pilot. None of them can fund a renewal. If nobody whose annual budget is measured on the outcome you improve signed the pilot, the conversion conversation starts from zero with a stranger.
The value accrued to a party that was not paying. This is the defining pathology of the sector. A tool that reduces readmissions saves the payer money in a fee-for-service hospital. A tool that improves adherence saves a plan money, not a clinic. A tool that saves nursing time saves labour cost that only materialises if the system actually reduces agency staffing, which it usually will not admit to planning. Follow the dollar precisely, and if it does not land in the pocket of the person signing, you do not have a business, you have a public good.
The pilot proved the wrong thing. Satisfaction scores, usage rates and clinician quotes are pilot outputs. Budget conversations need a number in the currency of the buyer: hours, beds, avoided transfers, coded revenue, staffing ratio, denial rate. If your pilot did not instrument that number on day one, you cannot retrofit it in the renewal meeting.
Integration cost exceeded the value. A system will absorb significant integration pain for a platform. It will not absorb it for a point solution saving a modest amount in one department. Every additional interface, SSO configuration, security review and data-use agreement raises the value threshold you must clear. Many companies price as a point solution and cost the buyer like a platform.
Nobody owned the operational change. Software does not deliver a clinical outcome. A changed workflow does. If the pilot depended on a nurse champion doing extra work on goodwill, the results end when she rotates, and the renewal is evaluated against those decayed results.
How to design a pilot that converts
The fix happens before the pilot starts, not during it.
Contract for the conversion at the outset. The pilot agreement should name the metric, the threshold, the evaluation date and, critically, the budget line and named owner who will fund the expansion if the threshold is met. Systems will sign this. Founders rarely ask, because they are afraid of losing the pilot. Losing a pilot that could never convert is the cheapest possible outcome.
Instrument the buyer's metric, not yours. Agree the data source, the baseline period and the analysis method with the system's own analytics team before go live, so the result is produced by their people in their format. A number your dashboard generates is marketing. A number their finance team generates is procurement evidence.
Price for the second year. Discounting the pilot to near zero establishes an anchor you will never recover from, and it also tells the organisation the product is not worth budgeting for. A pilot with real money attached gets real attention.
Limit the scope brutally. One service line, one workflow, one question, one measurable outcome. Broad pilots produce ambiguous results, and ambiguous results default to no.
Assign the operational owner in writing. Name the person responsible for the workflow change on the customer side, and make their time commitment explicit in the agreement. If the system will not name someone, they are not serious, and you have learned that for free.
The uncomfortable conclusion
Most health-technology companies raise a seed round on a thesis, spend it acquiring pilots, and interpret pilot volume as traction. Pilot volume is not traction. Pilot volume with a two percent conversion rate is a very expensive form of customer research.
The companies that break out are not the ones with the best clinical evidence or the best product. They are the ones that solved for the buyer's budget line before they solved for anything else. That is a less inspiring sentence than most founders want to hear, and it is the difference between a company and a project.
